EPIM 001
Alternative Names: EPIM-001Latest Information Update: 13 Apr 2022
At a glance
- Originator Elpis Biopharmaceuticals
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Interleukin-2 receptor alpha subunit modulators; Interleukin-2 receptor beta subunit agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 11 Apr 2022 Pharmacodynamics data from a preclinical study in Solid tumors presented at the annual meeting of the American Association for Cancer Research (AACR-2022)
- 08 Apr 2022 Elpis Biopharmaceuticals plans to file an IND application for Solid tumours in Q2 2022
- 18 Mar 2021 EPIM 001 is available for licensing as of 18 Mar 2021. https://elpisbiopharmaceuticals.com/partnering/ (Elpis Biopharmaceuticals pipeline, March 2021)